Matteo Alberto B.
- Country
- Italy
- Department
- Gastroenterology
Research Overview
- Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Duvakitug for Induction Therapy in Moderately to Severely Active Crohn's Disease
- Efficacy and Safety of Duvakitug for Maintenance Therapy in Participants with Moderately to Severely Active Crohn’s Disease: A Phase 3, Randomized, Placebo-Controlled Study
- Long‑Term Safety and Efficacy of SPY001‑001 Monotherapy and Combination Therapy with Long‑Acting Antibodies in Adults with Ulcerative Colitis
Data & Insights
Has run more than one trial at 195 of 240 partner sites.
Specializations
Inflammatory Bowel Disease Research
Specializing in advanced therapeutic approaches for Ulcerative Colitis, with particular focus on innovative treatment modalities for patients with moderate to severe disease manifestations.
- Autoimmune Gastrointestinal Disorders
- Inflammatory Disease Management
- Novel Therapeutic Applications
Primary interest in evaluating new therapeutic agents for chronic inflammatory conditions affecting the digestive system.
Immunology Studies
Investigates advanced immunomodulatory treatments targeting specific inflammatory pathways in gastrointestinal disorders.
- Immune System Regulation
- Inflammatory Response Mechanisms
- Targeted Therapy Development
Focuses on understanding immune system responses in chronic inflammatory conditions of the digestive tract.
Clinical Therapeutics
Explores the application of targeted biological therapies in treating inflammatory bowel conditions, with emphasis on improving patient outcomes.
- Treatment Efficacy Assessment
- Patient Response Evaluation
- Therapeutic Safety Profiles
Dedicated to advancing treatment options for patients with moderate to severe gastrointestinal inflammatory conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.